There were seven non-fatal strokes in patients with no RAS and one nonfatal stroke in patients with RAS, and this difference was not significant between two groups by Fisher's exact test ( P = 1.
There were 23 first rehospitalizations for cardiac failure during follow-up, 5 in RAS patients and 18 in non-RAS patients.
Two ischemic heart failure patients with non-RAS and 3 ischemic heart failure patients with RAS received hemodialysis therapy.
There were 56 patients, including 15 RAS patients and 41 non-RAS patients, who developed composite endpoint events during follow-up, and the difference between two groups was statistically significant (Chi-square = 7.
Ten patients with RAS received anti-angiotensin therapy and 63 patients with non-RAS received anti-angiotensin therapy.
In this study, we analyzed the association of RAS with clinical outcome in patients with heart failure.
Previous studies had investigated the association of RAS and long-term outcome of a patient with heart failure and have achieved controversial results.
We think that a threshold of severity exists for RAS to affect the future outcome.
Since RAS is associated with a poor outcome, it is worth to investigate whether renal revascularization is beneficial for patients with heart failure.